NCT00895830已完成2 期
Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 257
- 试验地点
- 16
- 主要终点
- Experienced Post-operative Nausea or Vomiting
研究概览
简要总结
To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ≥ 18 years of age
- •Written informed consent
- •Patients undergoing elective surgery under general anaesthesia requiring at least one overnight stay in hospital for either:
- •Hysterectomy (any surgical technique)
- •Cholecystectomy (any surgical technique)
- •Other elective surgery requiring overnight admission to hospital and scheduled to last at least 1 hour from induction of anaesthesia
- •Patients with at least 2 risk factors for PONV, defined as 2 of the following:
- •Past history of PONV and/or motion sickness
- •Non-smoking status
- •Female gender
- •Planned opiate use for post-operative analgesia
- •American Society of Anesthesiologists (ASA) risk score I-III (see Appendix 3)
- •Adequate hepatic and renal function
- •Alanine aminotransferase (ALT) <2.5 * upper limit normal (ULN)
- •Aspartate aminotransferase (AST) <2.5 * ULN
- •Bilirubin <1.5 * ULN
- •Creatinine <1.5 * ULN
- •Adequate haematological function
- •Haemoglobin ≥9.5 g/dL
- •White blood count 4.0-11.0 * 10^9/L
- •Platelet count ≥150 - 400 * 10^9/L
- •Ability and willingness to give written informed consent
排除标准
- •Patients undergoing outpatient/day case surgery
- •Patients undergoing surgery where the patient is expected to remain ventilated for a period after surgery
- •Patients undergoing intra-thoracic, transplant or central nervous system surgery
- •Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural) block
- •Patients receiving monoamine oxidase inhibitor (MAOI) therapy currently or in the preceding 3 weeks
- •Patients with a pre-existing vestibular disorder or history of dizziness
- •Patients that are expected to need a naso- or oral-gastric tube in situ after surgery is completed
- •Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study
- •Patients treated with regular anti-emetic therapy including corticosteroids
- •Patients receiving CYP3A4 inducers or inhibitors within 7 days prior to study including but not limited to erythromycin, itraconazole, nefazodone, diltiazem, verapamil, rifampicin
- •Patients with pre-existing nausea or vomiting 24 hours before surgery
- •Patients who are breast feeding or pregnant
- •Patients with a history of alcohol abuse
- •Patients diagnosed with Parkinson's disease
- •Patients who have received anti-cancer chemotherapy in the previous 4 weeks
- •Patients with pre-existing clinically significant cardiac arrhythmia
- •Patients with a history of epilepsy
- •Patients who have participated in a previous study within the last 28 days (French sites only: Patients who have participated in a previous study within the last 6 months, if required by national or local regulations)
研究组 & 干预措施
1
Placebo Comparator
干预措施: Placebo (Drug)
2
Experimental
0.3mg dose level
干预措施: APD405 (Drug)
3
Experimental
1mg dose level
干预措施: APD405 (Drug)
4
Experimental
2mg dose level
干预措施: APD405 (Drug)
5
Experimental
3mg dose level
干预措施: APD405 (Drug)
结局指标
主要结局
Experienced Post-operative Nausea or Vomiting
时间窗: 24 hours
次要结局
未报告次要终点
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Phase II Dose-ranging Study of APD421 in PONVPostoperative Nausea and VomitingNCT01510704Acacia Pharma Ltd215
已完成
2 期
Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following BunionectomyAcute Postoperative PainBunionectomyNCT04855240ACADIA Pharmaceuticals Inc.239
招募中
2 期
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)Cervical CancerNCT05872724Suzhou Municipal Hospital32
撤回
4 期
Antibiotics and Tissue Expanders in Breast ReconstructionBreast Prosthesis, Infection or Inflammation ComplicationsNCT01899690Emory University
招募中
Unknown
A Randomized Controlled Trial of Postoperative Abdominal Drain Placement in Minimally Invasive Liver SurgeryPrimary or metastatic liver tumorJPRN-UMIN000053024Department of Surgery and Science, Kyushu University182